Long-term outcome of childhood IgA nephropathy with minimal proteinuria. 2015

Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
Department of Pediatrics, Wakayama Medical University, 811-1 Kimiidera, Wakayama City, Wakayama, 641-8509, Japan.

BACKGROUND Some patients with childhood immunoglobulin A nephropathy (IgAN) progress to end-stage renal disease within 20 years, while others achieve spontaneous remission even without medication. Prognosis of IgAN with minimal proteinuria (MP-IgAN, <0.5 g/day/1.73 m(2)) at diagnosis seems to be generally good. However, the long-term outcome for patients with childhood MP-IgAN has not yet been determined. METHODS We retrospectively analyzed 385 children newly diagnosed with biopsy-proven IgAN between June 1976 and July 2009 whose renal biopsy specimens could be evaluated by the Oxford classification criteria. Of these 385 children with IgAN, 106 (27.5%) were diagnosed with MP-IgAN. We compared clinical and pathological findings between the 106 patients with MP-IgAN and the remaining 279 patients to elucidate the characteristics of MP-IgAN in children. RESULTS Patients with MP-IgAN were identified through a school screening program (73.6%) or upon presentation with gross hematuria (26.4%). Patients with MP-IgAN had significantly milder pathological symptoms than those with IgAN. The most frequently used therapeutic regimes were angiotensin converting enzyme inhibitors (30.2%) and no therapy (36.8%). None of the patients with MP-IgAN reached stage III chronic kidney disease within 15 years after onset. Four patients with MP-IgAN (3.8 %) received immunosuppressive therapy during the course of the disease. CONCLUSIONS Our results indicate that the outcome of patients with a diagnosis of childhood MP-IgAN is good, but that careful long-term observation is required.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005922 Glomerulonephritis, IGA A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE. Berger Disease,Immunoglobulin A Nephropathy,Nephropathy, IGA,Berger's Disease,IGA Glomerulonephritis,IGA Nephropathy,Iga Nephropathy 1,Nephritis, IGA Type,Bergers Disease,Glomerulonephritides, IGA,IGA Type Nephritis,Nephropathy 1, Iga,Nephropathy, Immunoglobulin A
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
October 2012, Journal of the American Society of Nephrology : JASN,
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
October 2012, Journal of the American Society of Nephrology : JASN,
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
January 2016, Indian journal of nephrology,
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
January 2016, PloS one,
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
August 2016, Journal of nephrology,
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
December 2020, Clinical nephrology,
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
January 2024, Pediatric nephrology (Berlin, Germany),
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
January 2014, American journal of nephrology,
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
November 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Asumi Higa, and Yuko Shima, and Taketsugu Hama, and Masashi Sato, and Hironobu Mukaiyama, and Hiroko Togawa, and Ryojiro Tanaka, and Kandai Nozu, and Mayumi Sako, and Kazumoto Iijima, and Koichi Nakanishi, and Norishige Yoshikawa
March 2001, Medicina clinica,
Copied contents to your clipboard!